腹腔镜远端胃切除术与开腹远端胃切除术对I期胃癌患者长期生存的影响:KLASS-01随机临床试验
KLASS-01是一项III期、多中心、开放标签、非劣效性、前瞻性随机临床试验,纳入1416例I期胃腺癌患者,1:1随机接受腹腔镜远端胃切除术(705例)或开腹远端胃切除术(711例)。结果显示,腹腔镜组5年总生存率为94.2%,开腹组为93.3%(log-rank P=0.64),意向性分析证实腹腔镜组非劣效于开腹组(差值0.9个百分点;单侧97.5%CI,-1.6至无穷)。结论认为,对于I期胃癌,腹腔镜远端胃切除术是肿瘤学安全的替代选择。
要点
- 腹腔镜远端胃切除术5年总生存率94.2%,开腹组93.3%,两组相似(log-rank P=0.64)。
- 意向性分析证实腹腔镜组非劣效于开腹组(差值0.9个百分点;单侧97.5%CI,-1.6至无穷)。
- 两组5年癌症特异性生存率相似(97.1% vs 97.2%,log-rank P=0.91)。
核心结论
- KLASS-01试验显示,腹腔镜远端胃切除术与开腹远端胃切除术患者的总体生存率和癌症特异性生存率相似。
- 对于I期胃癌,腹腔镜远端胃切除术是肿瘤学安全的开腹手术替代选择。
研究设计与样本
- 韩国腹腔镜胃肠外科研究(KLASS)组(包括13个机构的15名外科医生)开展了III期、多中心、开放标签、非劣效性、前瞻性随机临床试验(KLASS-01)。
- 研究对象为组织学证实、术前临床分期为I期的胃腺癌患者,入组时间为2006年1月5日至2010年8月23日。
- 患者按1:1随机分配至腹腔镜远端胃切除术组(n=705)或开腹远端胃切除术组(n=711)。
- 共1416例患者纳入研究,平均(标准差)年龄57.3(11.1)岁,男性940例(66.4%)。
- 患者的生存和复发状态于2016年12月确定。
主要发现
- 腹腔镜组5年总生存率为94.2%,开腹组为93.3%(log-rank P=0.64)。
- 意向性分析证实腹腔镜组非劣效于开腹组(差值0.9个百分点;单侧97.5%CI,-1.6至无穷)。
- 腹腔镜组5年癌症特异性生存率为97.1%,开腹组为97.2%(log-rank P=0.91;差值-0.03个百分点;单侧97.5%CI,-1.8至无穷)。
- 符合方案分析结果与意向性分析结果在总生存率和癌症特异性生存率方面一致。
- 在纳入患者中,85例接受了与随机分组相反的手术方式(63例随机至开腹组,22例随机至腹腔镜组)。
关键数值与推荐
- 非劣效性界值预设为-5%(对应风险比1.54),假设开腹手术组5年生存率为90%。
临床怎么用
- 对于I期胃癌,腹腔镜远端胃切除术是肿瘤学安全的开腹手术替代选择。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Laparoscopic distal gastrectomy is gaining popularity over open distal gastrectomy for gastric cancer because of better early postoperative outcomes. However, to our knowledge, no studies have proved whether laparoscopic distal gastrectomy is oncologically equivalent to open distal gastrectomy. OBJECTIVE: To examine whether the long-term survival among patients with stage I gastric cancer undergoing laparoscopic distal gastrectomy is noninferior to that among patients undergoing open distal gastrectomy. DESIGN: The Korean Laparoendoscopic Gastrointestinal Surgery Study (KLASS) group, which includes 15 surgeons from 13 institutes, conducted a phase 3, multicenter, open-label, noninferiority, prospective randomized clinical trial (KLASS-01) of patients with histologically proven, preoperative clinical stage I gastric adenocarcinoma from January 5, 2006, to August 23, 2010. Survival and recurrence status of the patients was determined in December 2016. INTERVENTIONS: Patients were randomly assigned (1:1) to laparoscopic distal gastrectomy (n = 705) or open distal gastrectomy (n = 711). Of these patients, 85 received a surgical approach opposite the one to which they were randomized (63 randomized to the open surgery group and 22 to the laparoscopic group). MAIN OUTCOMES AND MEASURES: Difference in 5-year overall survival between the laparoscopic and open distal gastrectomy groups. The noninferiority margin was prespecified as -5% (corresponding hazard ratio of 1.54), with an assumed survival of 90% after 5 years in the open surgery group. RESULTS: Among the 1416 patients (mean [SD] age, 57.3 [11.1] years; 940 [66.4%] male) included in the study, the 5-year overall survival rates were 94.2% in the laparoscopic group and 93.3% in the open surgery group (log-rank P = .64). Intention-to-treat analysis confirmed the noninferiority of the laparoscopic approach compared with the open approach (difference, 0.9 percentage points; 1-sided 97.5% CI, -1.6 to infinity). The 5-year cancer-specific survival rates were similar between the 2 groups (97.1% in the laparoscopic group and 97.2% in the open surgery group, log-rank P = .91; difference, -0.03 percentage points; 1-sided 97.5% CI, -1.8 to infinity). Per-protocol analysis results were consistent with the intention-to-treat results for overall and cancer-specific survival rates. CONCLUSIONS AND RELEVANCE: The KLASS-01 trial revealed similar overall and cancer-specific survival rates between patients receiving laparoscopic and open distal gastrectomy. Laparoscopic distal gastrectomy is an oncologically safe alternative to open surgery for stage I gastric cancer. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT00452751.
引用
- Kim HH, Han SU, Kim MC, et al. Effect of Laparoscopic Distal Gastrectomy vs Open Distal Gastrectomy on Long-term Survival Among Patients With Stage I Gastric Cancer: The KLASS-01 Randomized Clinical Trial. JAMA Oncol. 2019. PMID: 30730546. doi:10.1001/jamaoncol.2018.6727
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。